Both palbociclib and a broad-spectrum pan-CDK inhibitor AT7519 had a significant impact on MM cell lines and PDX tumors harboring abnormalities in CDK4 pathway (Table 2, Figure 4). The gene discussed is CDK4; the disease is Miyoshi myopathy.